Donepezil Hydrochloride Sandoz Ltd (Donepezil Hydrochloride)

Donepezil Hydrochloride is indicated for the symptomatic treatment of mild to moderate Alzheimer’s disease, aiming to support cognitive function and daily activities.

• Improves memory, attention, and language abilities in patients with early‑stage Alzheimer’s disease.
• May help maintain the ability to perform everyday tasks such as dressing and cooking.
• Used as part of a comprehensive care plan that includes non‑pharmacologic interventions.
• Can be prescribed when cholinesterase inhibitor therapy is considered appropriate by a healthcare professional.
• May be continued as disease progresses, provided tolerability and clinical benefit are assessed.

Side effects reported with Donepezil Hydrochloride vary in frequency and severity; they are categorized as common (typically mild) and serious (requiring medical attention).

Common

• Nausea, vomiting, or loss of appetite, especially when therapy is initiated.
• Diarrhea or abdominal cramps that usually improve with continued use.
• Insomnia or vivid dreams affecting sleep quality.
• Muscle cramps or weakness, often transient.
• Dizziness or light‑headedness, particularly after standing up quickly.
• Headache that is mild to moderate in intensity.

Serious

• Severe bradycardia or heart block that may cause fainting.
• Hepatotoxicity indicated by elevated liver enzymes or jaundice.
• Allergic reactions such as rash, angioedema, or anaphylaxis.
• Seizures or convulsions, though rare, may occur and need urgent evaluation.
• Psychiatric symptoms such as agitation, depression, or hallucinations that worsen.

When prescribing Donepezil Hydrochloride, clinicians should consider several precautions to ensure patient safety and monitor for potential complications.

• Assess cardiac history, especially bradyarrhythmias, before initiating therapy.
• Monitor liver function tests periodically, as hepatic impairment may increase drug exposure.
• Use caution in patients with asthma or chronic obstructive pulmonary disease, as cholinergic effects may exacerbate bronchospasm.
• Evaluate for gastrointestinal ulcer disease, since increased gastric secretions can aggravate existing lesions.
• Review concomitant medications that may lower heart rate or interact with cytochrome P450 enzymes.
• Consider dose adjustment in renal impairment, as excretion may be reduced.
• Inform patients about the possibility of vivid dreams and advise them to report persistent sleep disturbances.

Donepezil Hydrochloride can interact with several medicines; understanding which combinations to avoid or use cautiously helps prevent adverse effects.

Avoid

• Concurrent use with strong CYP3A4 inhibitors (e.g., ketoconazole) may increase plasma concentrations.
• Combination with other cholinesterase inhibitors (e.g., rivastigmine) can lead to excessive cholinergic activity.
• Co‑administration with drugs that cause bradycardia (e.g., beta‑blockers) may result in severe heart rate reduction.

Use with caution

• Anticholinergic agents (e.g., diphenhydramine) may diminish the therapeutic effect of donepezil.
• Non‑steroidal anti‑inflammatory drugs can increase the risk of gastrointestinal bleeding when combined with donepezil.
• Caution is advised when prescribing with anticoagulants, as donepezil may affect platelet function.